Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03057795
Recruitment Status : Recruiting
First Posted : February 20, 2017
Last Update Posted : October 31, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:
This phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab and brentuximab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Condition or disease Intervention/treatment Phase
Classic Hodgkin Lymphoma Hematopoietic Cell Transplant Recipient Recurrent Hodgkin Lymphoma Refractory Hodgkin Lymphoma Biological: Brentuximab Drug: Brentuximab Vedotin Other: Laboratory Biomarker Analysis Biological: Nivolumab Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. Assess the efficacy of nivolumab plus brentuximab vedotin consolidation after autologous stem cell transplantation (ASCT) in participants with relapsed/refractory Hodgkin lymphoma (HL), as assessed by 18-month progression-free survival (PFS).

SECONDARY OBJECTIVES:

I. Estimate the overall survival (OS), the cumulative incidence of relapse/progression, the cumulative incidence of non-relapse mortality (TRM) in participants with relapsed/ refractory HL who receive nivolumab plus brentuximab vedotin consolidation after ASCT.

II. Estimate the overall response rate to nivolumab plus brentuximab vedotin therapy in participants with measurable disease after ASCT.

III. Establish the safety and tolerability of nivolumab plus brentuximab vedotin when used as consolidation after ASCT in participants with relapsed/ refractory HL.

TERTIARY OBJECTIVES:

I. Evaluate the Lymphoma Response to Immunomodulatory therapy Criteria (LYRIC) definition of indeterminate response to guide the management of patients regarding treatment past progressive disease.

II. Explore the impact of nivolumab plus brentuximab vedotin therapy on immune reconstitution after ASCT.

III. Explore the prognostic impact of and temporal dynamics of minimal residual disease (MRD) in the peripheral blood as assessed by the next-generation sequencing-based ClonoSEQ platform.

IV. Explore the prognostic impact of 9p24.1 abnormalities in tumor tissue assessed by fluorescence in situ hybridization (FISH) on outcomes after ASCT and nivolumab plus brentuximab vedotin post-ASCT consolidation therapy.

V. Explore the relationship between immune cells and Hodgkin and Reed/Sternberg (HRS) in tumor samples by 6-color quantitative spatial image analysis using the Vectra system, and correlate with outcome after ASCT and nivolumab plus brentuximab vedotin post-ASCT consolidation therapy.

VI. Explore whether genetic alterations (e.g. gene expression profiles or genetic mutations) in HL tumor samples are associated with outcome after ASCT and nivolumab plus brentuximab vedotin post-ASCT consolidation therapy.

OUTLINE:

Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin intravenously (IV) over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 and 100 days, at 3, 6, 12, and 18 months from start of treatment, and then biannually thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
Actual Study Start Date : April 3, 2017
Estimated Primary Completion Date : October 8, 2020
Estimated Study Completion Date : October 8, 2020


Arm Intervention/treatment
Experimental: Treatment (brentuximab vedotin, nivolumab)
Beginning 30-60 days post-ASCT, patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Biological: Brentuximab
Given IV
Other Names:
  • Anti-CD30 Monoclonal Antibody
  • CAC-10
  • CAC10
  • Monoclonal Antibody SGN-30
  • SGN-30
  • SGN30

Drug: Brentuximab Vedotin
Given IV
Other Names:
  • ADC SGN-35
  • Adcetris
  • Anti-CD30 Antibody-Drug Conjugate SGN-35
  • Anti-CD30 Monoclonal Antibody-MMAE SGN-35
  • Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35
  • cAC10-vcMMAE
  • SGN-35

Other: Laboratory Biomarker Analysis
Correlative studies

Biological: Nivolumab
Given IV
Other Names:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo




Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: From the first dose of study treatment to the first observation of disease relapse/progression or death from any cause, whichever occurs first, assessed at 18 months ]
    Progression-free survival will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error. When there is no censoring in progression-free survival prior to 18 months after the first dose of study treatment, the observed 18-month progression-free survival will be compared to the baseline of 65% by one-sided exact test of binomial proportion. In case of censoring in progression-free survival prior to 18 months after the first dose of study treatment, the Kaplan-Meier estimate for 18-month progression-free survival along with the Greenwood standard error estimator will be used for the testing of null hypothesis at 65%.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: From the first dose of study treatment to death from any cause, assessed up to 18 months ]
    Overall survival will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error.

  2. Cumulative incidence of relapse/progression defined as the time from the first dose of study treatment to disease relapse/progression [ Time Frame: Up to 18 months ]
    Cumulative incidence of relapse/progression as well as its confidence intervals will be estimated using competing risk methodology, treating the other event as a competing risk.

  3. Cumulative incidence of non-relapse mortality defined as the time from the first dose of study treatment to non-disease related death [ Time Frame: Up to 18 months ]
    Cumulative incidence of non-relapse mortality as well as its confidence intervals will be estimated using competing risk methodology, treating the other event as a competing risk.

  4. Overall response rate [ Time Frame: Up to 18 months ]
    Overall response rate will be estimated by the proportion of patients achieving either complete response or partial response among participants with measurable disease after autologous stem cell transplantation, along with the exact binomial confidence interval.

  5. Incidence of toxicities evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 [ Time Frame: Up to 18 months ]
    Observed toxicities will be summarized by type (organ affected or laboratory determination such as absolute neutrophil count), severity (by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 and nadir or maximum values for lab measures), date of onset, duration, reversibility, and attribution.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented informed consent
  • Agreement to allow the use of archival tissue from pre-ASCT tumor biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Histologically confirmed diagnosis of classical Hodgkin lymphoma (excluding nodular lymphocyte predominant Hodgkin lymphoma) according to the World Health Organization (WHO) classification, with hematopathology review at the participating institution
  • Have high-risk relapsed or refractory Hodgkin lymphoma (HL), defined as at least one of the following:

    • Primary refractory disease to front-line therapy
    • Relapse within 1 year of completing front-line therapy
    • Extranodal involvement at the time of pre-ASCT relapse
    • B symptoms at pre-ASCT relapse
    • More than one type of pre-ASCT salvage therapy required
  • Planning to receive or have received autologous stem cell transplantation (ACST) per institutional standards as part of standard of care

    • Pre-ASCT participants may consent but will not be eligible to begin treatment until after ASCT, and will have to fulfill all inclusion and exclusion criteria before starting protocol
    • All participants must initiate day 1 of protocol therapy within 30-60 days post stem cell reinfusion; study PI can grant exception for a patient to start as late as 75 days post stem cell reinfusion with a reasonable justification for a delay (e.g. recovery from post -ASCT toxicity) and this will not be a protocol deviation, nor require an exception to be filled
  • Recovery from ASCT toxicity as defined as outpatient status, able to drink, eat normally, and do not need intravenous hydration prior to day 1 of therapy
  • Achieved at least stable disease to salvage treatment determined by positron emission tomography (PET)/computed tomography (CT) using 2014 Lugano Classification prior to ASCT
  • Brentuximab vedotin naive OR had at least stable disease by Lugano Classification to prior brentuximab vedotin treatment
  • Absolute neutrophil count (ANC) >= 1000/mm^3
  • Platelets >= 50,000/mm^3
  • Hemoglobin >= 8 g/dL
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) or 3 x ULN for Gilbert's disease
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
  • Creatinine clearance >= 40 mL/min per 24 hour urine collection or the Cockcroft-Gault formula
  • Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for hemoglobin [Hb]) >= 50% adjusted
  • Women of childbearing potential (WOCBP) only: Negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG])

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Woman of childbearing potential (WOCBP): use two effective methods of contraception (hormonal or barrier method) or be surgically sterile, or abstain from heterosexual activity for the course of the study through 7 months post last dose of nivolumab

    • WOCBP defined as not being surgically sterilized or have not been free from menses for > 1 year
    • Male: use two effective methods of contraception (barrier method) or abstain from heterosexual activity with the first dose of study therapy through 7 months post last dose of nivolumab

Exclusion Criteria:

  • Post-ASCT anti-lymphoma or investigational therapy; immediate post-ASCT consolidative radiation therapy is allowed as long as it occurs prior to initiation of study therapy; baseline imaging and pulmonary function tests (PFTs) must be performed after completion of radiation
  • Previous allogeneic transplant
  • Total carmustine (BCNU) dose of > 600 mg/m^2 with prior treatments including transplant conditioning regimen
  • Live vaccine within 30 days prior to day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette?Guerin [BCG], oral polio vaccine, and oral typhoid)
  • Refractory to prior brentuximab vedotin (i.e. progression while on treatment)
  • Refractory to prior anti-PD-1/PD-L1 agent
  • History of prior >= grade 3 hypersensitivity to either brentuximab vedotin or nivolumab
  • History of another primary malignancy that has not been in remission for at least 3 years; exceptions include:

    • Basal cell carcinoma of the skin or
    • Squamous cell carcinoma of the skin that has undergone potentially curative therapy or
    • In situ cervical cancer
  • Known active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitis
  • History of progressive multifocal leukoencephalopathy (PML)
  • Grade >= 2 peripheral neuropathy at the present time
  • Prior diagnosis of inherited or acquired immunodeficiency
  • Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration; exceptions are:

    • Inhaled or topical steroids and
    • Adrenal replacement doses > 10 mg daily prednisone equivalents in the absence of active autoimmune disease
  • Uncontrolled illness including ongoing or active infection
  • History of or active pneumonitis or interstitial lung disease:

    • For history of pneumonitis to be an exclusion, patient had to have required supplemental oxygen or corticosteroid treatment; radiographic changes alone are not an exclusion
  • An active, known or suspected autoimmune disease; the following are exceptions:

    • Vitiligo
    • Hemolytic anemia associated with the lymphoma (history of or at the present time)
    • Type I diabetes mellitus
    • Residual hypothyroidism due to autoimmune condition only requiring hormone replacement
    • Psoriasis not requiring systemic treatment, or
    • Conditions not expected to recur in the absence of an external trigger
  • Active or known history (standard pre-ASCT assessments) of:

    • Hepatitis B or C infection
    • Human immunodeficiency virus (HIV)
    • Acquired immunodeficiency syndrome (AIDS)
  • Women who are pregnant or lactating
  • History of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association Class III-IV within 6 months prior to day 1 of protocol therapy
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03057795


Locations
Layout table for location information
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Alex Herrera    626-256-4673 ext 62405    aherrera@coh.org   
Principal Investigator: Alex Herrera         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Patrick B. Johnston    507-266-4671    johnston.patrick@mayo.edu   
Principal Investigator: Patrick B. Johnston         
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Tatyana A. Feldman    551-996-3033    Tatyana.Feldman@hackensackmeridian.org   
Principal Investigator: Tatyana A. Feldman         
United States, New York
Memorial Sloan Kettering Cancer Center Not yet recruiting
New York, New York, United States, 10065
Contact: Gunjan L. Shah       shahg@mskcc.org   
Principal Investigator: Gunjan L. Shah         
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Yago L. Nieto    713-792-8750    ynieto@mdanderson.org   
Principal Investigator: Yago L. Nieto         
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109
Contact: Leona A. Holmberg    206-667-6447    lholmber@fredhutch.org   
Principal Investigator: Leona A. Holmberg         
Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Alex F Herrera City of Hope Medical Center
Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT03057795    
Other Study ID Numbers: 16378
NCI-2017-00222 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
16378 ( Other Identifier: City of Hope Comprehensive Cancer Center )
P30CA033572 ( U.S. NIH Grant/Contract )
First Posted: February 20, 2017    Key Record Dates
Last Update Posted: October 31, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Immunological
Nivolumab
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunoconjugates
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents